Abstract: A rotary wheel humidity regulating device, an air conditioning system having same, a control method for an air conditioning system, and a controller. The rotary wheel humidity regulating device includes an adsorption rotary wheel, a first heat exchanger, and a second heat exchanger. The adsorption rotary wheel has a first portion located at an air inlet side of a fresh air system of an air conditioning system and a second portion located at an air return side of the fresh air system. The first heat exchanger is disposed at a position on the air return side, is in communication with a refrigerant circuit of the air conditioning system, and is controlled for cooling or heating by the air conditioning system through the refrigerant circuit. The second heat exchanger is disposed at a position on the air inlet side close to the first portion, is in communication with the refrigerant circuit, and is controlled for cooling or heating by the air conditioning system through the refrigerant circuit.

Abstract: The disclosure belongs to the technical field of additive manufacturing, and discloses a flexible piezoelectric sensor based on 4D printing and a preparation method thereof. The sensor includes a magnetic part and a conductive part, wherein: the conductive part includes two substrates disposed opposite to each other and a spiral structure disposed between the two substrates. Both the two substrates and the spiral structure are made of conductive metal materials. The magnetic part has a flexible porous structure and is arranged between the two substrates to generate a magnetic field. When the substrate is subjected to external pressure, the spiral structure and the magnetic part are compressed simultaneously, the magnetic flux passing through the spiral structure changes, and the voltage of the two substrates changes, by measuring the voltage change of the two substrates to reflect the change of external pressure, the pressure measuring process is achieved.

Abstract: The disclosure relates to a PIC structure including a photonic component on a semiconductor substrate. Each of a plurality of optical guard elements are composed of a light absorbing material and are in proximity to the photonic component. The optical guard elements may mimic an outer periphery of at least a portion of the photonic component. The optical guard elements may include at least one of: a germanium body positioned at least partially in a silicon element, a silicon body having a high dopant concentration, and a polysilicon body having a high dopant concentration over the silicon body.

Abstract: Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.

Abstract: The invention discloses a method for preparing a ruthenium rotary sputtering target, including the following steps: S100: manually press molding: putting ruthenium powder into a mold, and manually pressurizing the ruthenium powder to form the ruthenium powder into a relative density is a first preformed target with a first preset density; S200: vacuum hot pressing, placing the first stage target together with the mold into a vacuum hot press for processing to obtain a second preformed target with a relative density of the second preset density The preformed target material, and the second preset density is bigger than the first preset density; S300: hot isostatic pressing, the second preformed target material is put into the hot isostatic pressing for processing, and the relative density of the third preformed target is obtained. Assuming the density of the forming target, the third preset density is bigger than the second preset density, and the third preset density is exceeded 99.5%.

Abstract: A compound represented by formula (I) or a stereoisomer, a tautomer, a crystal form, a pharmaceutically acceptable salt, a hydrate, a solvate or a prodrug thereof are provided. The compound represented by formula (I) can be used as a kinase inhibitor for preparing a medicament for treating diseases mediated by kinase such as ROS1, NTRK and ALK.

Abstract: A compound useful as a CDK7 kinase inhibitor has a structure shown in formula I The definition of each group and substituent is as described in the description. The compound invention can be used as an inhibitor of cyclin-dependent kinase 7 (CDK7) for the treatment or prevention of proliferative diseases (such as cancers), and in particular for the regulation and treatment of related diseases caused by abnormal activity of cyclin-dependent kinase 7 (CDK7).

Abstract: The present invention relates to the technical field of medicines. Specifically disclosed is a compound as represented by formula I?, or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, symbols therein being as defined in the claims. The compound of the present invention may be used as a drug for regulating RET kinase activity or treating RET-related diseases, and has good pharmacokinetic properties.

Abstract: A kinase inhibitor compound of formula I or a pharmaceutically acceptable salt, solvate, or prodrug thereof. The compound has good inhibitory activity on EGFR and Her2 exon 20 insertion mutation, EGFR exon 19 deletion and L858R point mutation of exon 21.

Abstract: The present invention relates to a compound used as an RET kinase inhibitor and an application thereof. The compound has a structure represented by formula F, has a good inhibitory ability for RET kinase, and has relatively good pharmacodynamic and pharmacokinetic performance, and lower toxic side effects.

Abstract: The present invention relates to a compound used as a kinase inhibitor and to the use thereof. The structure of the compound is as shown in formula I. The present compound used as a kinase inhibitor has good inhibitory activity on EGFR and Her2 exon 20 insertion mutations, and has excellent potential to be developed into a drug for treating related diseases.

Abstract: The present invention relates to a compound used as an EGFR kinase inhibitor and the use thereof. The compound has a structure as shown in formula I, and can be used to adjust the kinase activity or treat related diseases, especially non-small cell lung cancer.

Abstract: The present invention belongs to the field of medical technology and specifically disclosed is a compound represented by formula (I?), or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and each symbol therein is as defined in the claims. The compound of the present invention may be used as a drug for regulating RET kinase activity or treating RET-related diseases, and has better pharmacokinetic properties.

Abstract: The present disclosure relates to a tobacco flavoring machine, comprising: a drum (1) capable of rotating about an axis thereof as a rotation center; a nozzle (6) disposed in the drum (1) to spray a liquid flavor to tobacco shreds in the drum (1); and a shoveling plate (5) arranged on an inner wall (11) of the drum (1) and extending from an inlet end of the drum (1) towards the interior of the drum (1), the shoveling plate (5) being disposed obliquely with respect to a generatrix (9) of the drum (1). The present disclosure improves the problem of the related art that tobacco shreds cannot flow smoothly from an inlet end toward an outlet end because a shoveling plate (5) is parallel to an axis of a drum (1).

Abstract: Provided is the compound represented by formula I, or tautomer thereof, or meso thereof, racemate thereof, and mixture of meso and racemate thereof, or enantiomer thereof, diastereomer, and mixture of enantiomer and diastereomer, or pharmaceutically acceptable salt thereof, or deuterate thereof. The compound of formula I can be used as a kinase inhibitor, as a drug for the treatment of ROS1, NTRK, ALK, and other kinase-mediated diseases.

Abstract: The present disclosure relates generally to the field of antimicrobial compounds and to methods of making and using them. In some embodiments, the present disclosure provides pyrrolo[2,3-d]pyrimidin-2-ones useful for treating, preventing, reducing the risk of, and delaying the onset of microbial infections in humans and animals.

Abstract: The present invention is directed to a [1,3]thiazin-2-amine compound, an application and a pharmaceutical composition, belongs to the field of BACE inhibitors. The [1,3]thiazin-2-amine compound is a compound represented by formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof. The compound has a good inhibitory effect on BACE and can be used in preparing a medicament for treating a neurodegenerative disease, such as Alzheimer's disease.

Abstract: A crystal form of a deuterated AZD9291 has an X-ray powder diffraction measured using Cu-K? rays with diffraction peaks at 7.1±0.2, 8.5±0.2, 9.4±0.2, 10.3±0.2, 15.1±0.2, 16.3±0.2, 18.7±0.2, 22.0±0.2, 25.6±0.2, and 26.0±0.2. The crystal form of the deuterated AZD9291 is used in the preparation of medicaments for the treatment of cancer. The crystal form of the deuterated AZD9291 provided by the present invention has stable physical and chemical properties and good metabolic stability, and blood concentrations in vivo and concentrations in the brain thereof are significantly improved, achieving an improved therapeutic effect.

Abstract: A crystal form of a deuterated AZD9291 has an X-ray powder diffraction measured using Cu-K? rays with diffraction peaks at 7.1±0.2, 8.5±0.2, 9.4±0.2, 10.3±0.2, 15.1±0.2, 16.3±0.2, 18.7±0.2, 22.0±0.2, 25.6±0.2, and 26.0±0.2. The crystal form of the deuterated AZD9291 is used in the preparation of medicaments for the treatment of cancer. The crystal form of the deuterated AZD9291 provided by the present invention has stable physical and chemical properties and good metabolic stability, and blood concentrations in vivo and concentrations in the brain thereof are significantly improved, achieving an improved therapeutic effect.

Abstract: The present invention is directed to a [1,3]thiazin-2-amine compound, an application and a pharmaceutical composition, belongs to the field of BACE inhibitors. The [1,3]thiazin-2-amine compound is a compound represented by formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof. The compound has a good inhibitory effect on BACE and can be used in preparing a medicament for treating a neurodegenerative disease, such as Alzheimer's disease.